Mipomersen: Evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia

Core Evidence

Volumn 7, Issue , 2012, Pages 29-38

  Parhofer, Klaus G ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antisense oligonucleotide; Apolipoprotein B; Statin intolerance

Indexed keywords

AMINOTRANSFERASE; ANACETRAPIB; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; BILE ACID SEQUESTRANT; CHOLESTERYLESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; APHERESIS; ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; EVIDENCE BASED MEDICINE; FAMILIAL HYPERCHOLESTEROLEMIA; FLU LIKE SYNDROME; GENE MUTATION; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HOMOZYGOUS FAMILIAL CHOLESTEROLEMIA; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERTHYROIDISM; INJECTION SITE ERYTHEMA; LIFESTYLE MODIFICATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84870409612     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S25239     Document Type: Review

References (41)

1. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214-225. (Pubitemid 46502094)
2. Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci U S A. 1974;71(3):788-792.
3. Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973;70(10):2804-2808.
4. Gaffney D, Reid JM, Cameron IM, et al. Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler Thromb Vasc Biol. 1995;15(8):1025-1029.
5. Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B100. Proc Natl Acad Sci U S A. 1989;86(2):587-591. (Pubitemid 19037786)
6. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154-156. (Pubitemid 36666925)
7. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272.
8. Robinson JG, Goldberg AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(Suppl 3):S18-S29.
9. Sjouke B, Kusters DM, Kastelein JJ, Hovingh GK. Familial hypercholesterolemia: present and future management. Curr Cardiol Rep. 2011;13(6):527-536.
10. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
11. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267- 1278.
12. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.
13. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124(20):2202-2207.
14. Elis A, Zhou R, Stein EA. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am J Cardiol. 2011;108(2):223-226.
15. Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther. 2010;32(4):615-625.
16. Thompson GR. Lipoprotein apheresis. Curr Opin Lipidol. 2010;21(6):487-491.
17. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis. 2010;208(2):317-321.
18. American Society For Apheresis. Therapeutic apheresis: a guide to billing and securing appropriate reimbursement, 2006. Available from: http://www.apheresis.org/~ASSETS/DOCUMENT/PDF/Committee/Therapeutic%20Apheresis- A%20Guide%20to%20Billing%20and%20Securing%20Appropriate%20Reimbursement%20(2006) .pdf. Accessed April 24, 2012.
19. Kucukkartallar T, Yankol Y, Kanmaz T, Topaloglu S, Acarli K, Kalayoglu M. Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia. Pediatr Transplant. 2011;15(3):281-284.
20. Brown WV, Bays H, Davidson M, Goldberg A. Drugs in development for management of lipoprotein disorders. J Clin Lipidol. 2011;5(2):66-75.
21. Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106(24): 9820-9825.
22. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A. 2008;105(33):11915-11920.
23. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res. 2007;48(4):763-767. (Pubitemid 46557881)
24. Konrad RJ, Troutt JS, Cao G. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis. 2011;10:38.
25. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010;362(10):906-916.
26. Barkowski RS, Frishman WH. HDL metabolism and CETP inhibition. Cardiol Rev. 2008;16(3):154-162. (Pubitemid 351549677)
27. Raval SK, Raval PS, Jain MR. Emerging therapies for dyslipidemia: known knowns and known unknowns of MTP inhibitors. Recent Pat Endocr Metab Immune Drug Discov. 2012;6(1):24-29.
28. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337-345.
29. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259-293.
30. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114(16):1729-1735. (Pubitemid 44607121)
31. Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet. 2009;48(1):39-50.
32. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105(10):1413- 1419.
33. Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010;55(15):1611-1618.
34. Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011;32(21):2650-2659.
35. Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M. Safety and efficacy of mipomersen administered as add-on therapy in patients with hypercholesterolemia and high cardiovascular risk. J Am Coll Cardiol. 2011:Abstract.
36. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998-1006.
37. Stein E, Dufour R, Gagne C, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on-therapy in herterozygous familial hyoercholesterolemia patients wirh coronary artery disease. Eur Heart J. 2010;31 Suppl 1:Abstract.
38. Tardif JC, Ceska R, Burgess LJ, et al. Apolipoprotein B-synthesis inhibition by mipomersen reduces LDL-C when added to maximally tolerated lipid-lowering medication in patients with severe heterozygous hypercholesterolemia. J Am Coll Cardiol. 2011:Abstract.
39. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. April 16, 2012. [Epub ahead of print.]
40. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010;51(5):1057-1062.
41. Parhofer KG, Vogt A. 760 mipomersen and apoB synthesis inhibitor evaluation of potential to reduce necessity for lipid-apheresis in patients with heterozygous FH and CAD. Atherosclerosis. 2011;12(1):159.